The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It proactively corrects for glucose highs every five minutes and protects against lows with insulin dosing.
Insulet’s Omnipod 5 App for iPhone offers full control of Omnipod 5, including the ability to bolus, change a pod, adjust settings, access insights and more. Users can now download the new app with Dexcom G7 and G6 compatibility from the Apple App Store.
Dexcom and Insulet have a longstanding relationship as far as integrated technologies. Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 in early 2024. The FDA cleared the iPhone app in October 2023, then the company fully launched its iPhone app in the U.S. in October 2024. However, that launch came with only G6 compatibility, as the company slated a G7 rollout for 2025.
“This integration represents a major milestone in our commitment to providing innovative solutions for diabetes management,” said Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.”
